pharma&
Lei Tian is a Finance Director at pharma& since January 2021. Prior to this role, Lei held various finance positions at Pfizer, Montana Tech Components AG, PwC Austria, and other companies, gaining experience in finance, accounting, and corporate finance management. Lei's expertise lies in strategic planning, financial analysis, business partnering, and implementing finance processes. With a Master's degree in Accounting and Finance from WU (Vienna University of Economics and Business), Lei has a strong educational background to support their professional experience.
pharma&
1 followers
pharmaand GmbH (pharma&), a privately owned global company, aspires to breathe new life into proven medicines through our agile and fully integrated business model, guaranteeing the enduring availability, dependability, and quality of essential drugs worldwide that patients and healthcare providers rely on. Whether a former blockbuster or niche medicine, we acquire the worldwide rights to specialty treatments to secure long-term access to established and essential medicines across various specialized therapy areas, doing whatever it takes to maintain and develop the value of these medicines for all who depend on them. We’ve acquired and integrated 11 medicines over the past five years, expanding our portfolio across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments. Our unique, fully integrated model across pharma&’s subsidiaries, joint ventures, and partners enables us to provide our portfolio of medicines to eligible healthcare providers and patients worldwide, spanning the continuum of manufacturing, distribution, administration/access, and patient support.